Susquehanna Portfolio Strategies LLC Sells 16,533 Shares of Exscientia plc (NASDAQ:EXAI)

Susquehanna Portfolio Strategies LLC lowered its holdings in shares of Exscientia plc (NASDAQ:EXAI) by 49.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,777 shares of the company’s stock after selling 16,533 shares during the period. Susquehanna Portfolio Strategies LLC’s holdings in Exscientia were worth $86,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the business. Bank of New York Mellon Corp grew its holdings in shares of Exscientia by 108.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 388,459 shares of the company’s stock worth $1,981,000 after purchasing an additional 202,377 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Exscientia in the 2nd quarter worth $256,000. EntryPoint Capital LLC boosted its holdings in Exscientia by 22.8% during the first quarter. EntryPoint Capital LLC now owns 31,171 shares of the company’s stock worth $178,000 after buying an additional 5,784 shares during the last quarter. Federated Hermes Inc. acquired a new position in Exscientia during the second quarter valued at approximately $115,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in shares of Exscientia in the 2nd quarter valued at $54,000. 41.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Barclays reissued an “equal weight” rating and set a $5.00 target price on shares of Exscientia in a research note on Tuesday, August 13th. TD Cowen reissued a “hold” rating on shares of Exscientia in a research note on Friday, August 9th.

Exscientia Price Performance

Shares of EXAI opened at $5.06 on Monday. The company’s 50-day moving average is $5.19 and its 200-day moving average is $5.18. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.93 and a quick ratio of 5.93. The firm has a market capitalization of $611.69 million, a PE ratio of -3.86 and a beta of 0.86. Exscientia plc has a fifty-two week low of $3.80 and a fifty-two week high of $7.91.

Exscientia (NASDAQ:EXAI) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.05). Exscientia had a negative net margin of 620.99% and a negative return on equity of 37.56%. The business had revenue of $5.60 million during the quarter. Equities analysts forecast that Exscientia plc will post -1.25 EPS for the current year.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.